#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14746	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2256	650.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1582	1582	C	838	C	768	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27688	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3574	772.4	0	.	n	.	0	T695C	SNP	695	695	T	994	994	C	854	C	800	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27688	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3574	772.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1636	1636	A	940	A	863	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27688	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3574	772.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2270	2270	C	848	C	778	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27688	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3574	772.4	0	.	n	.	0	C2172T	SNP	2172	2172	C	2471	2471	T	887	T,C	833,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27688	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3574	772.4	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2896	2896	T	835	T,C	789,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27688	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3574	772.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2344	2344	A	895	A	842	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1966	folP	852	852	100.0	folP.l6.c30.ctg.1	1384	140.8	1	SNP	p	R228S	1	.	.	682	684	AGC	935	937	AGC	203;203;202	A;G;C	185;187;186	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5438	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3385	160.0	1	SNP	p	S91F	0	.	.	271	273	TCC	580	582	TCC	183;182;185	T;C;C	172;172;176	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5438	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3385	160.0	1	SNP	p	D95N	0	.	.	283	285	GAC	592	594	GAC	183;184;183	G;A;C	173;170;171	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5438	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3385	160.0	1	SNP	p	D95G	0	.	.	283	285	GAC	592	594	GAC	183;184;183	G;A;C	173;170;171	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	1710	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1355	125.8	1	SNP	p	G45D	1	.	.	133	135	GAC	512	514	GAC	211;212;213	G;A;C	192;194;195	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	940	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	934	99.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5316	parC	2304	2304	99.74	parC.l6.c30.ctg.1	2937	180.2	0	.	p	.	0	L479F	NONSYN	1435	1437	CTT	1790	1792	TTT	241;240;239	T;T;T	231;226;229	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5316	parC	2304	2304	99.74	parC.l6.c30.ctg.1	2937	180.2	1	SNP	p	D86N	0	.	.	256	258	GAC	611	613	GAC	198;199;203	G;A;C	190;190;196	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5316	parC	2304	2304	99.74	parC.l6.c30.ctg.1	2937	180.2	1	SNP	p	S88P	0	.	.	262	264	TCC	617	619	TCC	202;205;207	T;C;C	190;195;198	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4350	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2794	155.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1690	1692	GGC	192;188;188	G;G;C	176;176;172	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3894	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2425	159.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1280	1282	GCA	199;199;198	G;C;A	182;184;187	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3894	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2425	159.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1283	1285	ATC	198;198;198	A;T;C	188;187;186	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3894	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2425	159.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1295	1297	GTG	200;202;203	G;T;G,A	191;189;185,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3894	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2425	159.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1295	1297	GTG	200;202;203	G;T;G,A	191;189;185,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3894	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2425	159.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1799	1801	ACC	212;212;211	A;C;C	187;192;191	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3894	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2425	159.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1853	1855	GCG	210;210;209	G;C;G	186;167;173	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3894	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2425	159.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1853	1855	GCG	210;210;209	G;C;G	186;167;173	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3894	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2425	159.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1976	1978	GGC	155;154;155	G;G;C,T	142;142;142,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3894	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2425	159.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1985	1987	GGC	158;158;158	G,A;G;C	144,1;143;145	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3894	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2425	159.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2003	2005	CCG	144;145;143	C,G;C;G,A	103,3;108;102,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5774	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3044	189.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1575	1577	CTG	187;187;186	C;T;G	172;172;173	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2522	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1876	133.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	657	657	C	171	C	155	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	G38E	NONSYN	112	114	GGA	460	462	GAA	234;231;231	G;A;A	221;219;219	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	S46G	NONSYN	136	138	AGC	484	486	GGC	210;207;208	G;G;C	200;198;198	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	E48G	NONSYN	142	144	GAA	490	492	GGA	216;217;218	G;G;A	203;202;203	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	T87A	NONSYN	259	261	ACT	607	609	GCT	212;212;213	G;C;T	201;200;200	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	T89S	NONSYN	265	267	ACC	613	615	AGC	211;211;213	A;G;C	198;199;200	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	.	MULTIPLE	358	359	AA	705	706	CG	198;197	C;G	187;185	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	.	MULTIPLE	361	362	GA	708	710	CAG	195;197;198	C;A;G	183;186;189	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	N122K	NONSYN	364	366	AAC	712	714	AAA	200;199;199	A;A;A	190;188;188	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	K143E	NONSYN	427	429	AAA	775	777	GAA	193;194;193	G;A;A	182;182;181	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	V151A	NONSYN	451	453	GTA	799	801	GCA	216;216;219	G;C;A	200;198;200	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	A215T	NONSYN	643	645	GCT	991	993	ACT	201;202;204	A;C;T	188;188;191	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1000	1002	ATG	205;203;199	A;T;G	187;188;181	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1114	1116	GCA	230;226;229	G;C;A	219;216;216	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1117	1119	ACG	227;226;231	A;C;G	218;214;219	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	S258R	NONSYN	772	774	AGT	1120	1122	AGG	229;230;228	A;G;G	218;218;219	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1123	1125	GTT	228;228;229	G;T;T	217;213;216	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1183	1185	GTA	252;251;248	G;T;A,G	227;224;226,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1222	1224	ACT	252;252;253	A;C;T	232;238;239	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1228	1230	GAT	247;247;250	G;A;T	234;231;235	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1240	1242	CAC	249;246;241	C;A;C	229;226;223	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	1	SNP	p	G120K	1	.	.	358	360	AAG	705	707	CGG	198;197;195	C;G;G	187;185;185	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	1	SNP	p	D121N	0	.	.	361	363	GAC	708	711	CGC	195;198;196	C;G;C,A	183;189;185,1	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2664	porB1b	1047	1047	97.14	porB1b.l15.c4.ctg.1	1540	172.3	1	SNP	p	A121D	1	.	.	361	363	GAC	708	711	CGC	195;198;196	C;G;C,A	183;189;185,1	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10294	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4623	221.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1848	1850	AAT	246;248;246	A;A;T	230;232;229	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1152	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1167	98.4	1	SNP	p	V57M	1	.	.	169	171	ATG	580	582	ATG	252;252;248	A;T;G	240;241;235	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
